Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo

Päivi Lindholm, Merja H. Voutilainen, Juha Laurén, Johan Peränen, Veli-Matti Leppänen, Jaan-Olle Andressoo, Maria Lindahl, Sanna Janhunen, Nisse Kalkkinen, Tõnis Timmusk, Raimo K. Tuominen and Mart Saarma ()
Additional contact information
Päivi Lindholm: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Merja H. Voutilainen: Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Juha Laurén: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Johan Peränen: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Veli-Matti Leppänen: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Jaan-Olle Andressoo: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Maria Lindahl: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Sanna Janhunen: Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Nisse Kalkkinen: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Tõnis Timmusk: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Raimo K. Tuominen: Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
Mart Saarma: Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland

Nature, 2007, vol. 448, issue 7149, 73-77

Abstract: Neuronal rescue The drugs currently available for Parkinson's disease patients generally treat only the symptoms, and do not prevent the degeneration and death of dopaminergic neurons in the brain, the cause the motor defects associated with the disease. Treatment with glial cell line-derived neurotrophic factor (GDNF) has had limited success, but there are safety concerns. Lindholm et al. report the discovery and purification of a new neurotrophic factor, called conserved dopamine neurotrophic factor (CDNF), that can also prevent degeneration of dopaminergic neurons in a rat model of Parkinson's disease. In rats with established Parkinson's disease, CDNF even induces some recovery of dopaminergic function. A paper in last week's Nature identified calcium antagonists as a possible means of rejuvenating dopaminergic neurons, so it seems that at last there are several lines of research that might one day lead to genuinely effective antiparkinsons drugs.

Date: 2007
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature05957 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:448:y:2007:i:7149:d:10.1038_nature05957

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature05957

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().